News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
375,529 Results
Type
Article (14779)
Company Profile (114)
Press Release (360636)
Multimedia
Podcasts (38)
Webinars (7)
Section
Business (116373)
Career Advice (469)
Deals (19191)
Drug Delivery (30)
Drug Development (32160)
Employer Resources (50)
FDA (8928)
Job Trends (7831)
News (178214)
Policy (12854)
Tag
Academia (1455)
Accelerated approval (3)
Allergies (43)
Alliances (35393)
ALS (32)
Alzheimer's disease (540)
Antibody-drug conjugate (ADC) (81)
Approvals (8967)
Artificial intelligence (256)
Autoimmune disease (5)
Automation (14)
Bankruptcy (134)
Best Places to Work (6661)
BIOSECURE Act (8)
Biosimilars (11)
Biotechnology (86)
Bladder cancer (31)
Brain cancer (13)
Breast cancer (125)
Cancer (1123)
Cardiovascular disease (69)
Career advice (421)
Career pathing (12)
CAR-T (112)
Cell therapy (285)
Cervical cancer (11)
Clinical research (25368)
Collaboration (640)
Compensation (121)
Complete response letters (3)
COVID-19 (1188)
CRISPR (41)
C-suite (157)
Cystic fibrosis (48)
Data (1093)
Decentralized trials (1)
Denatured (18)
Depression (17)
Diabetes (112)
Diagnostics (5033)
Digital health (17)
Diversity (4)
Diversity, equity & inclusion (9)
Drug discovery (80)
Drug pricing (14)
Drug shortages (4)
Duchenne muscular dystrophy (26)
Earnings (40907)
Editorial (2)
Employer branding (8)
Employer resources (43)
Events (52987)
Executive appointments (435)
FDA (9672)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (3)
Funding (501)
Gene editing (94)
Generative AI (25)
Gene therapy (187)
GLP-1 (238)
Government (1333)
Grass and pollen (2)
Guidances (90)
Healthcare (10168)
Huntington's disease (5)
IgA nephropathy (12)
Immunology and inflammation (34)
Indications (13)
Infectious disease (1266)
Inflammatory bowel disease (70)
Inflation Reduction Act (3)
Influenza (33)
Intellectual property (66)
Interviews (53)
IPO (8355)
IRA (8)
Job creations (1456)
Job search strategy (372)
Kidney cancer (4)
Labor market (10)
Layoffs (123)
Leadership (3)
Legal (2596)
Liver cancer (38)
Lung cancer (141)
Lymphoma (71)
Machine learning (7)
Management (17)
Manufacturing (201)
MASH (16)
Medical device (11606)
Medtech (11611)
Mergers & acquisitions (11209)
Metabolic disorders (230)
Multiple sclerosis (31)
NASH (3)
Neurodegenerative disease (35)
Neuropsychiatric disorders (4)
Neuroscience (757)
NextGen: Class of 2025 (3634)
Non-profit (1683)
Now hiring (9)
Obesity (96)
Opinion (81)
Ovarian cancer (43)
Pain (53)
Pancreatic cancer (43)
Parkinson's disease (73)
Partnered (13)
Patents (161)
Patient recruitment (61)
Peanut (26)
People (33959)
Pharmaceutical (16)
Phase I (9281)
Phase II (11458)
Phase III (7428)
Pipeline (682)
Policy (36)
Postmarket research (537)
Preclinical (4211)
Press Release (67)
Prostate cancer (48)
Psychedelics (4)
Radiopharmaceuticals (166)
Rare diseases (141)
Real estate (3432)
Recruiting (20)
Regulatory (9771)
Reports (18)
Research institute (1323)
Resumes & cover letters (69)
Rett syndrome (5)
RNA editing (2)
RSV (23)
Schizophrenia (13)
Series A (90)
Series B (56)
Service/supplier (7)
Sickle cell disease (19)
Special edition (1)
Spinal muscular atrophy (58)
Sponsored (13)
Startups (2533)
State (2)
Stomach cancer (3)
Supply chain (29)
Tariffs (6)
The Weekly (19)
Vaccines (331)
Venture capitalists (19)
Weight loss (36)
Women's health (18)
Worklife (2)
Date
Today (54)
Last 7 days (486)
Last 30 days (1585)
Last 365 days (17313)
2025 (6249)
2024 (19131)
2023 (22685)
2022 (31374)
2021 (33162)
2020 (31280)
2019 (26552)
2018 (20059)
2017 (19325)
2016 (18189)
2015 (21143)
2014 (15630)
2013 (13047)
2012 (14131)
2011 (14479)
2010 (13162)
Location
Africa (334)
Alabama (43)
Alaska (6)
Arizona (129)
Arkansas (10)
Asia (24821)
Australia (4315)
California (3188)
Canada (1113)
China (281)
Colorado (180)
Connecticut (137)
Delaware (57)
Europe (50372)
Florida (516)
Georgia (142)
Idaho (36)
Illinois (299)
India (13)
Indiana (173)
Iowa (5)
Japan (125)
Kansas (86)
Kentucky (8)
Louisiana (7)
Maine (21)
Maryland (486)
Massachusetts (2237)
Michigan (199)
Minnesota (264)
Mississippi (2)
Missouri (62)
Montana (24)
Nebraska (15)
Nevada (27)
New Hampshire (67)
New Jersey (977)
New Mexico (16)
New York (926)
North Carolina (556)
North Dakota (8)
Northern California (1211)
Ohio (112)
Oklahoma (11)
Oregon (21)
Pennsylvania (635)
Puerto Rico (11)
Rhode Island (25)
South America (572)
South Carolina (23)
South Dakota (1)
Southern California (1320)
Tennessee (65)
Texas (528)
United States (12538)
Utah (115)
Virginia (63)
Washington D.C. (15)
Washington State (353)
West Virginia (3)
Wisconsin (41)
375,529 Results for "interna technologies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
InteRNA Technologies Establishes Clinical Advisory Board and Appoints New Members to Scientific Advisory Board
InteRNA Technologies, a clinical-stage biotech company developing microRNA -based therapeutics with a focus on cancer, announced the establishment of a Clinical Advisory Board and the appointment of new members to its Scientific Advisory Board.
October 19, 2021
·
7 min read
Business
InteRNA Appoints Established Oncology Innovator Andrea van Elsas, PhD, to its Supervisory Board
InteRNA Technologies, a clinical-stage biotech company developing microRNA -based therapeutics with a focus on cancer, announced the appointment of Andrea van Elsas, PhD, as a new member of the Company’s Supervisory Board.
October 12, 2021
·
4 min read
InteRNA Technologies Awarded € 2.7M Clinical Innovation Credit from Dutch Government
InteRNA Technologies, a clinical-stage biotech company developing microRNA -based therapeutics with a focus on cancer, announced that it was awarded a Clinical Innovation Credit of € 2.7 Million from the Dutch government.
March 11, 2021
·
3 min read
Drug Development
InteRNA Technologies Announces U.S. FDA Clearance of IND Application for Phase I Clinical Trial with Lead microRNA Candidate INT-1B3 in Patients with Advanced Solid Tumors
InteRNA Technologies announced it received Investigational New Drug clearance from the U.S. Food and Drug Administration for the company’s Phase I clinical trial evaluating lead miRNA candidate, INT-1B3, in patients with advanced solid tumors.
December 2, 2021
·
4 min read
Press Releases
Patent Granted to BC3 Technologies for SEAL Hemostatic Wound Spray
April 16, 2025
·
4 min read
Press Releases
Maxwell Biosciences Secures US Military Agreement to Research Scientific Aspects of Claromer Technology
U.S. Army Institute of Surgical Research to conduct key studies intended to further our knowledge of the effects of Claromer technology
March 5, 2025
·
2 min read
Press Releases
MicroSurgical Technology (MST) Advances Leadership in Vitrectomy Technology with Presentations at ASCRS 2025 Annual Meeting
April 22, 2025
·
3 min read
InteRNA Technologies Announces Dosing of First Patient in First-in-Human Trial of microRNA Drug Candidate INT-1B3 in Patients with Advanced Solid Tumors
InteRNA Technologies announced that the first patient has been dosed in the first cohort of its first-in-human Phase I study with the Company’s lead microRNA candidate, INT-1B3.
February 16, 2021
·
3 min read
Press Releases
Palatin Technologies Announces Closing of Reduced Public Offering
May 9, 2025
·
5 min read
Press Releases
BioStem Technologies to Present at the Centri Capital Conference
April 22, 2025
·
1 min read
1 of 37,553
Next
